{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-030284","form_type":"8-K","ticker":"MLAB","cik":"0000724004","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.830055+00:00","generated_at":"2026-06-08T21:37:25.102636+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mesa Labs Q2 revenue down 9.5% to $53.2M, net loss of $1.23M","bullets":["Operating income turned negative at $(60), down 101.5% vs prior year.","Non-GAAP adj. operating income ex unusual items fell 29.1% to $11.2M.","Clinical Genomics down 15.7% organic on Sema4 loss ($8.2M annual headwind).","Biopharm Development revenues fell 24.4% organic, consumables up 4.7%.","Cost actions expected to save ~$2M annually starting in Q3; GKE acquisition closed Oct 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-030284","json":"https://secwatch.observer/filing/0001437749-23-030284.json","markdown":"https://secwatch.observer/filing/0001437749-23-030284.md","text":"https://secwatch.observer/filing/0001437749-23-030284.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724004/000143774923030284/0001437749-23-030284-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724004/000143774923030284/mlab20231103_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:37:25.102636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4bde6750c7767b9b92c0b65fdba78ee5b8b6ba9","claim":"MESA LABORATORIES INC /CO/ reported second fiscal quarter ended September 30, 2023 results: revenue $53,165, net income $(1,230), EPS $(0.23) per diluted share.","evidence_excerpt":"our Clinical Genomics division early in 3Q23 but was better than the first quarter for both revenues and AOI excluding unusual items. Total revenues for the second quarter were $53,165, which resulted in an organic revenue (“organic”) decline of 9.6% versus the same quarter in the prior year (“2Q23”), or a 5.0% sequential increase when compared to the first","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/724004/000143774923030284/0001437749-23-030284-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second fiscal quarter ended September 30, 2023"},{"label":"Revenue","value":"$53,165"},{"label":"Net income","value":"$(1,230)"},{"label":"EPS","value":"$(0.23) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}